NOTE: This article provided free of charge for all to read by The Washington Post.
Moderna said Wednesday that it has manufactured a new version of its coronavirus vaccine that is tailored to quell infection by the variant first identified in South Africa. A small amount of vaccine has been sent to the National Institutes of Health for a trial to determine whether boosting humans with the modified vaccine will stimulate a strong immune response, the company said.
The news came after the release of a Food and Drug Administration review finding the single-shot coronavirus vaccine made by pharmaceutical giant Johnson & Johnson safe and effective. The review sets the stage for a third coronavirus vaccine to be authorized in the United States as soon as this weekend. View the post.